Top

Infection

Published in:

01-04-2014 | Review

An Italian consensus for invasive candidiasis management (ITALIC)

Authors: L. Scudeller, C. Viscoli, F. Menichetti, V. del Bono, F. Cristini, C. Tascini, M. Bassetti, P. Viale

Published in: Infection | Issue 2/2014

Abstract

Introduction

Invasive candidiasis (IC) has primarily been studied in intensive care unit (ICU) patients, although, in reality, a vast majority of these infections occur outside of the ICU. The recent publication of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines also deal with the non-ICU population, but many uncertainties remain on the management of IC, particularly in non-critically ill patients.

Methods

The Italian Society of Antimicrobial Therapy, Società Italiana di Terapia Antimicrobica (SITA), produced practical, hospital-wide recommendations on the management of Candida infection in non-immunocompromised patients in the hospital ward.

Results and discussion

Our focus is on patient stratification in terms of risk factors for IC and of clinical severity, emphasising a high index of suspicion to ensure early diagnosis, early treatment and de-escalation when a patient is clinically stable, in order to optimise resource allocation.

Available only for authorised users

Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739–46. doi:10.1093/cid/cis305.PubMed

Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6:e24198. doi:10.1371/journal.pone.0024198.PubMedCentralPubMed

Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol. 1998;36:1886–9.PubMedCentralPubMed

Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24:584–602.PubMed

Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239–44. doi:10.1086/520192.PubMed

Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100:617–23 (pii:S0002934395000100).PubMed

Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg. 2000;135:160–5.PubMed

Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21. doi:10.1186/1471-2334-6-21.PubMedCentralPubMed

Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5. doi:10.1128/AAC.49.9.3640-3645.2005.PubMedCentralPubMed

10.

Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31. doi:10.1086/504810.PubMed

11.

Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother. 2010;65:1765–70. doi:10.1093/jac/dkq216.PubMed

12.

Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. doi:10.1086/596757.PubMed

13.

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2013;18:19–37. doi:10.1111/1469-0691.12039.

14.

Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284–1292. doi:10.1093/cid/cit006.PubMed

15.

Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6:e20476. doi:10.1371/journal.pone.0020476.PubMedCentralPubMed

16.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. doi:10.1136/bmj.39489.470347.AD.PubMedCentralPubMed

17.

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8. doi:10.1136/bmj.39490.551019.BE.PubMedCentralPubMed

18.

Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.PubMed

19.

Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–10. doi:10.1136/bmj.39500.677199.AE.PubMedCentralPubMed

20.

Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049–51. doi:10.1136/bmj.39493.646875.AE.PubMedCentralPubMed

21.

National Institute for Health and Clinical Excellence (NICE). The guidelines manual. Last updated January 2009.

22.

Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8. doi:10.1128/AAC.01128-10.PubMedCentralPubMed

23.

Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, et al. Candida spp. with acquired echinocandin resistance, France, 2004–2010. Emerg Infect Dis. 2012;18:86–90. doi:10.3201/eid1801.110556.PubMedCentralPubMed

24.

Viale P. Candida colonization and candiduria in critically ill patients in the intensive care unit. Drugs. 2009;69:51–7. doi:10.2165/11315640-000000000-00000.PubMed

25.

Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, Itzhaki A, Lazarovitch T, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol. 2008;46:2222–6. doi:10.1128/JCM.00214-08.PubMedCentralPubMed

26.

American College of Chest Physicians/Society of Critical Care. Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.

27.

Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–8.PubMedCentralPubMed

28.

Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235–43.PubMed

29.

Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271–6. doi:10.1007/s10096-007-0270-z.PubMed

30.

León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730–7. doi:10.1097/01.CCM.0000202208.37364.7D.PubMed

31.

León C, Ruiz-Santana S, Saavedra P, Galván B, Blanco A, Castro C, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–33. doi:10.1097/CCM.0b013e31819daa14.PubMed

32.

Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care. 2010;16:465–9. doi:10.1097/MCC.0b013e32833e0487.PubMed

33.

Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1 → 3)-beta-d-glucan assay, Candida score, and colonization index. Crit Care. 2011;15:R249. doi:10.1186/cc10507.PubMedCentralPubMed

34.

Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2009;54:46–51. doi:10.1111/j.1439-0507.2009.01756.x.

35.

Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care. 2010;16:470–4. doi:10.1097/MCC.0b013e32833e10e8.PubMed

36.

Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case–control study. Crit Care. 2011;15:R198. doi:10.1186/cc10366.PubMedCentralPubMed

37.

Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8. doi:10.1097/CCM.0b013e31819efac0.PubMed

38.

Charles PE, Castro C, Ruiz-Santana S, León C, Saavedra P, Martín E. Serum procalcitonin levels in critically ill patients colonized with Candida spp.: new clues for the early recognition of invasive candidiasis? Intensive Care Med. 2009;35:2146–50. doi:10.1007/s00134-009-1623-0.PubMed

39.

Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17:103–9 (pii:0732-8893(93)90020-8).PubMed

40.

Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H, Hedstrom U. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol. 2009;58:606–15. doi:10.1099/jmm.0.006452-0.PubMed

41.

Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222. doi:10.1186/cc9365.PubMedCentralPubMed

42.

Tokunaga S, Ohkawa M, Takashima M. Diagnostic value of determination of serum mannan concentrations in patients with candiduria. Eur J Clin Microbiol Infect Dis. 1993;12:542–5.PubMed

43.

Verduyn Lunel FM, Donnelly JP, van der Lee HA, Blijlevens NM, Verweij PE. Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect. 2009;15:380–6. doi:10.1111/j.1469-0691.2008.02654.x.PubMed

44.

Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarløv JO, Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect. 2009;16:855–62. doi:10.1111/j.1469-0691.2009.02931.x.PubMed

45.

Hsu JL, Ruoss SJ, Bower ND, Lin M, Holodniy M, Stevens DA. Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol. 2011;37:277–312. doi:10.3109/1040841X.2011.581223.PubMed

46.

Laín A, Elguezabal N, Moragues MD, García-Ruiz JC, del Palacio A, Pontón J. Contribution of serum biomarkers to the diagnosis of invasive candidiasis. Expert Rev Mol Diagn. 2008;8:315–25. doi:10.1586/14737159.8.3.315.PubMed

47.

Preuner S, Lion T. Towards molecular diagnostics of invasive fungal infections. Expert Rev Mol Diagn. 2009;9:397–401. doi:10.1586/erm.09.27.PubMed

48.

Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-beta-d-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864–70. doi:10.1086/588295.PubMed

49.

Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205. doi:10.1086/421944.PubMed

50.

Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1 → 3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654–9. doi:10.1086/432470.PubMed

51.

Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568–73. doi:10.1097/QCO.0b013e3283321ce5.PubMedCentralPubMed

52.

Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012;54:1322–31. doi:10.1093/cid/cis132.PubMedCentralPubMed

53.

Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665–70. doi:10.1128/JCM.01602-10.PubMedCentralPubMed

54.

Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35:1526–31. doi:10.1007/s00134-009-1482-8.PubMed

55.

Gadea I, Cuenca-Estrella M, Martín E, Pemán J, Pontón J, Rodríguez-Tudela JL. Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing. Enferm Infecc Microbiol Clin. 2007;25:336–40; 13102270 [pii].PubMed

56.

Richardson M, Ellis M. Clinical and laboratory diagnosis. Hosp Med. 2000;61:610–4.PubMed

57.

Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glöckner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54:279–310. doi:10.1111/j.1439-0507.2011.02040.x.PubMed

58.

Clinical and Laboratory Standards Institute (CLSI). Principles and procedures for blood cultures; Approved guideline. CLSI document M47-A. Wayne, PA: CLSI; 2007.

59.

Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45:3546–8. doi:10.1128/JCM.01555-07.PubMedCentralPubMed

60.

Washington JA 2nd. Blood cultures: principles and techniques. Mayo Clin Proc. 1975;50:91–8.PubMed

61.

Cockerill FR 3rd, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, et al. Optimal testing parameters for blood cultures. Clin Infect Dis. 2004;38:1724–30. doi:10.1086/421087.PubMed

62.

Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45. doi:10.1086/599376.PubMed

63.

Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70. doi:10.1093/cid/ciq206.PubMed

64.

Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1 → 3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46:1009–13. doi:10.1128/JCM.02091-07.PubMedCentralPubMed

65.

Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, et al. Clinical performance of the (1,3)-beta-d-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol. 2011;18:2113–7. doi:10.1128/CVI.05408-11.PubMedCentralPubMed

66.

Eggimann P, Marchetti O. Is (1 → 3)-beta-d-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? Crit Care. 2011;15:1017. doi:10.1186/cc10544.PubMedCentralPubMed

67.

Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-beta-d-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis. 2009;13:707–12. doi:10.1016/j.ijid.2008.10.013.PubMed

68.

Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10:882–5.PubMedCentralPubMed

69.

Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1 → 3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43:5957–62. doi:10.1128/JCM.43.12.5957-5962.2005.PubMedCentralPubMed

70.

Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, Sasaki M, et al. Combined assessment of beta-d-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg. 2004;28:625–30. doi:10.1007/s00268-004-7302-y.PubMed

71.

Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, et al. Prospective survey of (1 → 3)-beta-d-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol. 2011;49:58–61. doi:10.1128/JCM.01240-10.PubMedCentralPubMed

72.

Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1 → 3)-beta-d-glucan assay for invasive fungal disease. Clin Infect Dis. 2009;49:1650–9. doi:10.1086/647942.PubMed

73.

Acosta J, Catalan M, Del Palacio-Pérez-Medel A, Montejo JC, De-La-Cruz-Bértolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-d-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis. 2011;31:721–31. doi:10.1007/s10096-011-1365-0.PubMed

74.

Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43. doi:10.1093/cid/cir897.PubMed

75.

Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, beta-d-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240–8. doi:10.1093/cid/cis200.PubMed

76.

Mokaddas E, Khan ZU, Ahmad S, Nampoory MR, Burhamah M. Value of (1–3)-beta-d-glucan, Candida mannan and Candida DNA detection in the diagnosis of candidaemia. Clin Microbiol Infect. 2011;17:1549–53. doi:10.1111/j.1469-0691.2011.03608.x.PubMed

77.

Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51:95–101. doi:10.1016/j.diagmicrobio.2004.08.015.PubMed

78.

Sendid B, Poirot JL, Tabouret M, Bonnin A, Caillot D, Camus D, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol. 2002;51:433–42.PubMed

79.

Nihtinen A, Anttila VJ, Richardson M, Ruutu T, Juvonen E, Meri T, et al. Factors influencing the performance level of Candida mannan antigen testing in allogeneic stem cell transplant recipients not receiving fluconazole prophylaxis. Transpl Infect Dis. 2011;13:266–72. doi:10.1111/j.1399-3062.2010.00593.x.PubMed

80.

Maaroufi Y, Heymans C, De Bruyne JM, Duchateau V, Rodriguez-Villalobos H, Aoun M, et al. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol. 2003;41:3293–8.PubMedCentralPubMed

81.

Moreira-Oliveira MS, Mikami Y, Miyaji M, Imai T, Schreiber AZ, Moretti ML. Diagnosis of candidemia by polymerase chain reaction and blood culture: prospective study in a high-risk population and identification of variables associated with development of candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:721–6. doi:10.1007/s10096-005-0041-7.PubMed

82.

Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin Microbiol Infect. 2008;14:37–45. doi:10.1111/j.1469-0691.2008.01980.x.PubMed

83.

Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore). 2009;88:160–8. doi:10.1097/MD.0b013e3181a693f8.

84.

Shoham S, Shaffer R, Sweet L, Cooke R, Donegan N, Boyce S. Candidemia in patients with ventricular assist devices. Clin Infect Dis. 2007;44:e9–12. doi:10.1086/509640.PubMed

85.

Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest. 2002;122:302–10.PubMed

86.

Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–22. doi:10.1093/cid/cis021.PubMed

87.

Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore). 2003;82:187–202. doi:10.1097/01.md.0000076008.64510.f1.

88.

Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology. 1982;89:789–96.PubMed

89.

Oude Lashof AM, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262–8. doi:10.1093/cid/cir355.PubMed

90.

Nagao M, Saito T, Doi S, Hotta G, Yamamoto M, Matsumura Y, et al. Clinical characteristics and risk factors of ocular candidiasis. Diagn Microbiol Infect Dis. 2012;73:149–52. doi:10.1016/j.diagmicrobio.2012.03.006.PubMed

91.

Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 → 3)-beta-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2012;18:E122–7. doi:10.1111/j.1469-0691.2012.03777.x.PubMedCentralPubMed

92.

Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-beta-d-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521–6. doi:10.1093/cid/cis456.PubMed

93.

Pazos C, Moragues MD, Quindós G, Pontón J, del Palacio A. Diagnostic potential of (1,3)-beta-d-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006;23:209–15 (pii:200623209).PubMed

94.

Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066–72.PubMed

95.

Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28:1708–17. doi:10.1007/s00134-002-1540-y.PubMed

96.

Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med. 2005;33:1928–35; quiz 36 (pii:00003246-200509000-00005).PubMed

97.

Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702 (pii:S1473309903008016).PubMed

98.

Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis. 2001;32:1191–200. doi:10.1086/319763.PubMed

99.

McKinnon PS, Goff DA, Kern JW, Devlin JW, Barletta JF, Sierawski SJ, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg. 2001;136:1401–8; discussion 9 (pii:soa1025).PubMed

100.

Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177–86. doi:10.1086/321811.PubMed

101.

Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;57:628–38. doi:10.1093/jac/dki491.PubMed

102.

Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542–8.PubMedCentralPubMed

103.

Faiz S, Neale B, Rios E, Campos T, Parsley E, Patel B, et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis. 2009;28:689–92. doi:10.1007/s10096-008-0666-4.PubMed

104.

Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med. 2006;34:1216–24. doi:10.1097/01.CCM.0000208357.05675.C3.PubMed

105.

Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37. doi:10.1186/1745-6215-10-37.PubMedCentralPubMed

106.

Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90; 149/2/83 [pii].PubMed

107.

Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:613–8. doi:10.1093/jac/dkm212.PubMed

108.

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136:1237–48. doi:10.1378/chest.09-0087.PubMed

109.

Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother. 2010;54:184–90. doi:10.1128/AAC.00945-09.PubMedCentralPubMed

110.

Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med. 2006;34:646–52. doi:10.1097/01.CCM.0000201889.39443.D2.PubMed

111.

Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061–7. doi:10.1111/j.1469-0691.2010.03360.x.PubMed

112.

Karthaus M, Rüping MJ, Cornely OA, Steinbach A, Groll AH, Lass-Flörl C, et al. Current issues in the clinical management of invasive candida infections—the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses. 2011;54:e546–56. doi:10.1111/j.1439-0507.2010.01988.x.PubMed

113.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51. doi:10.1093/jac/dkr244.PubMed

114.

Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, et al. The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia. 2011;171:85–91. doi:10.1007/s11046-010-9369-3.PubMed

115.

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother. 2012;56:3239–43. doi:10.1128/AAC.00019-12.PubMedCentralPubMed

116.

Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56:3950–6. doi:10.1128/AAC.06258-11.PubMedCentralPubMed

117.

Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518–23. doi:10.1128/AAC.05947-11.PubMedCentralPubMed

118.

Tortorano AM, Prigitano A, Dho G, Grancini A, Passera M. Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol. 2012;61:389–93. doi:10.1099/jmm.0.037895-0.PubMed

119.

van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59:952–6. doi:10.1093/jac/dkm074.PubMed

120.

Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–9. doi:10.1056/NEJMoa021585.PubMed

121.

Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519–27. doi:10.1016/S0140-6736(07)60605-9.PubMed

122.

Reboli AC, Shorr AF, Rotstein C, Pappas PG, Kett DH, Schlamm HT, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261. doi:10.1186/1471-2334-11-261.PubMedCentralPubMed

123.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883–93. doi:10.1086/520980.PubMed

124.

Glöckner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. Eur J Med Res. 2011;16:167–79.PubMedCentralPubMed

125.

Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–82. doi:10.1056/NEJMoa066906.PubMed

126.

Rodriguez D, Park BJ, Almirante B, Cuenca-Estrella M, Planes AM, Mensa J, et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect. 2007;13:788–93. doi:10.1111/j.1469-0691.2007.01758.x.PubMed

127.

Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc. 2008;83:1011–21. doi:10.4065/83.9.1011.PubMed

128.

Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;18:680–7. doi:10.1111/j.1469-0691.2012.03784.x.PubMedCentralPubMed

129.

Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2010;55:561–6. doi:10.1128/AAC.01079-10.PubMedCentralPubMed

130.

Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). Int J Antimicrob Agents. 2011;38:65–9. doi:10.1016/j.ijantimicag.2011.02.016.PubMed

131.

Cantón E, Pemán J, Quindós G, Eraso E, Miranda-Zapico I, Álvarez M, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother. 2011;55:5590–6. doi:10.1128/AAC.00466-11.PubMedCentralPubMed

132.

Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case–control study in Paris, France. Antimicrob Agents Chemother. 2011;55:5358–61. doi:10.1128/AAC.00690-11.PubMedCentralPubMed

133.

Spreghini E, Orlando F, Tavanti A, Senesi S, Giannini D, Manso E, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother. 2012;67:2195–202. doi:10.1093/jac/dks180.PubMed

134.

Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84. doi:10.1086/598933.PubMed

135.

Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13:R159. doi:10.1186/cc8117.PubMedCentralPubMed

136.

Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54:1774–7. doi:10.1093/cid/cis290.PubMed

137.

Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43:e29–38. doi:10.1086/505969.PubMed

138.

Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001;60:1452–9. doi:10.1046/j.1523-1755.2001.00948.x.PubMed

139.

Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964–72.PubMed

140.

Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325–30. doi:10.1056/NEJM199411173312001.PubMed

141.

Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337–45.PubMed

142.

Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56:3133–7. doi:10.1128/AAC.05841-11.PubMedCentralPubMed

143.

Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, et al. Voriconazole in clinical practice. J Chemother. 2012;24:311–27. doi:10.1179/1973947812Y.0000000051.PubMed

144.

Tuil O, Cohen Y. Itraconazole IV solution in the treatment of candidemia in non-neutropenic patients. Crit Care. 2003;7:P131.PubMedCentral

145.

Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect. 2011;17:1–12. doi:10.1111/j.1469-0691.2011.03615.x.PubMed

146.

Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect. 2008;56:126–9. doi:10.1016/j.jinf.2007.10.014.PubMed

147.

Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18:E99–109. doi:10.1111/j.1469-0691.2012.03764.x.PubMed

148.

Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648–53. doi:10.1093/cid/ciq204.PubMed

149.

Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42–7. doi:10.1001/archopht.122.1.42.PubMed

150.

Kujath P, Lerch K, Kochendörfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection. 1993;21:376–82.PubMed

151.

Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008;92:466–8. doi:10.1136/bjo.2007.133405.PubMed

152.

Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366:1435–42. doi:10.1016/S0140-6736(05)67490-9.PubMed

153.

Ozdemir H, Karbuz A, Ciftçi E, Dinçaslan HU, Ince E, Aysev D, et al. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses. 2011;54:e647–9. doi:10.1111/j.1439-0507.2010.01964.x.PubMed

154.

Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641–5. doi:10.1182/blood-2005-02-0733.PubMed

155.

Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997–2020 (pii:64181).PubMed

156.

Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728–32. doi:10.1086/377131.PubMed

157.

Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21:293–318 (pii:2144).PubMed

158.

Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301:126–31. doi:10.1056/NEJM197907193010303.PubMed

159.

Fan-Havard P, O’Donovan C, Smith SM, Oh J, Bamberger M, Eng RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis. 1995;21:960–5.PubMed

160.

Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections—treatment. Clin Infect Dis. 2011;52:S457–66. doi:10.1093/cid/cir112.PubMed

161.

Khazim RM, Debnath UK, Fares Y. Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J. 2006;15:1404–10. doi:10.1007/s00586-005-0038-z.PubMedCentralPubMed

162.

Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol. 2008;46:79–83. doi:10.1080/13693780701552996.PubMed

163.

Kaldau NC, Brorson S, Jensen PE, Schultz C, Arpi M. Bilateral polymicrobial osteomyelitis with Candida tropicalis and Candida krusei: a case report and an updated literature review. Int J Infect Dis. 2012;16:e16–22. doi:10.1016/j.ijid.2011.10.001.PubMed

164.

Slenker AK, Keith SW, Horn DL. Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. Diagn Microbiol Infect Dis. 2012;73:89–93. doi:10.1016/j.diagmicrobio.2012.02.004.PubMed

165.

Micafungin lock therapy to clear fungemia while attempting to preserve central venous catheters. Trial code: NCT00809887. http://clinicaltrials.gov/.

166.

McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O’Neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008;46:890–6. doi:10.1086/528690.PubMed

Title: An Italian consensus for invasive candidiasis management (ITALIC)
Authors: L. Scudeller
C. Viscoli
F. Menichetti
V. del Bono
F. Cristini
C. Tascini
M. Bassetti
P. Viale
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 2/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-013-0558-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results and discussion

Please log in to get access to this content

Other articles of this Issue 2/2014

Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern

Rothia aeria mitral valve endocarditis complicated by multiple mycotic aneurysms: laboratory identification expedited using MALDI-TOF MS

The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children

Comparison of clinical presentation and laboratory values at admission between PCR-confirmed influenza A H1N1 infection and influenza-like disease, South-East Austria

Validation of the CORB75 (confusion, oxygen saturation, respiratory rate, blood pressure, and age ≥75 years) as a simpler pneumonia severity rule

Development of universal influenza vaccines based on influenza virus M and NP genes

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage